Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial [Rapid Communications]
Conclusion
Trabectedin demonstrates superior disease control versus conventional dacarbazine in patients who have advanced liposarcoma and leiomyosarcoma after they experience failure of prior chemotherapy. Because disease control in advanced sarcomas is a clinically relevant end point, this study supports the activity of trabectedin for patients with these malignancies.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Demetri, von Mehren, Jones, Hensley, Schuetze, Staddon, Milhem, Elias, Ganjoo, Tawbi, Van Tine, Spira, Dean, Khokhar, Park, Knoblauch, Parekh, Maki, Patel Tags: Rapid Communications, Chemotherapy, Rhabdo & Other Soft Tissue Sarcomas: Source Type: research
More News: Cancer & Oncology | Chemotherapy | Clinical Trials | Leiomyosarcoma | Liposarcoma | Sarcomas | Soft Tissue Sarcoma | Study | Toxicology